UK Medtech Upscales International Plans Ahead of Brexit
Executive Summary
As the UK prepared to leave the EU, the local medtech industry, represented by the Association of British Healthcare Industries, has been busy finding ways to make up for any potential restrictions on market access and business development. On June 21, it announced a three-year growth plan, as explained by ABHI managing director of international Paul Benton in this Medtech Insight podcast interview.
You may also be interested in...
UK Medtech's US Innovation Hub Aims To Accentuate The Positive In Post-Brexit Phase
With Brexit moving ever closer, the UK medtech industry is trying to ensure that local manufacturers have a range of commercial options in overseas markets in the post-EU phase. The ABHI is playing a strong support role in this area, following up its recent international growth plan with a new US innovation hub, designed to offer outward-looking UK medtechs the tools to build positions in the world's largest market.
UK To Offset Brexit, Spur Global Growth With Life-Science Sector Deal And Industrial Strategy
The UK today revealed the bulk of its Industrial Strategy, as signaled by Prime Minister May's government in 2016. It's both a response and a proactive move in the wake of the controversial Brexit vote. It builds on the already-issued Life Sciences strategy, which earned the medtech industry's approbation this summer, and includes the "sector deal" for UK life sciences.
UK Medtechs Find Common Cause On Brexit In NHS Confed's Health Alliance
The UK has yet to get to the sharp end when it comes to the true effects of Brexit on future policy, trade and regulation, but the medtech industry and the national health-care provider, through the NHS Confederation, are pushing for a progressive and inclusive relationship with EU stakeholders. The Brexit Health Alliance is the latest embodiment of that drive.